Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI (OI)
What is the purpose of this trial?
This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
- Ages2 - 17 years
- Trial withAmgen, Inc.
- Start Date09/28/2017
- End Date02/14/2018
- Last Updated02/22/2018
- Study HIC#1501015168